Antibodies at work in the time of SARS-CoV-2
Imagenes y Videos
Abstract
Even after a decade of continuous emergence of coronaviruses, there aren’t any licenced
vaccines or therapeutics against the deadly infection. The age-old passive immunization with
protective antibodies to neutralize the virus is one of the strategies for emergency prophylaxis
and therapy for COVID-19. In this review, we discuss the up-to-date advances in immunebased therapy for COVID-19. The use of convalescent plasma therapy as the first line of
defences to treat SARS-CoV-2 infection has been established with encouraging results.
Monoclonal antibodies (mAbs) that bind to the receptor-binding domain (RBD) of SARSCoV-2 spike (S) protein or blocking the interaction between SARS-CoV-2 RBD and human
angiotensin-converting enzyme 2 (hACE2) receptor have been found very promising as the
countermeasure to tackle the SARS-CoV-2 infection, though clinical trials are underway.
Considering the counterproductive antibody-dependent enhancement of the virus, the mAbs
therapy that is safe and efficacious even in people with an underlying condition will be a
significant breakthrough. The emerging immunotherapeutic interventions using nanobodies
and cellular immunotherapy are also the promising avenues to tackle the COVID-19
pandemic. We also discuss the implication of mAbs against mediators of cytokine storm
syndrome to modify the immune response of COVID-19 patients, thus reducing the fatality
rate of COVID-19 infection.
Link to resource
https://doi.org/10.1016/j.jcyt.2020.08.009Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.